Table 1

Patient characteristics
Characteristics At time of inclusion At follow-up HCs
(n = 84) (n = 43) (n = 28)
Age in years (mean) 37 (35-39) 41 (38-43) 42.9
Gender, percentage female 58 59 57
Diagnosis, percentage of patients
Ankylosing spondylitis 19 19 -
Psoriatic arthritis 11 12 -
Enteropathic arthritis 4 5 -
Reactive arthritis 15 17 -
Undifferentiated SpA 51 47 -
HLA-B27, percentage positive 60 55 -
Disease duration in years (mean)a 8.0 (7.0-9.0) 12.6 (9.8-15) -
Treatment, percentage of patients
No 67 - -
MTX 8 - -
Salazopyrin 11 - -
Anti-TNFα 7 12 -
Self-assessment scores -
BASDAI, 0-100 (mean) 32 (26-37) 35 (28-42) -
BASFI, 0-100 (mean) 20 (16-25) 22 (16-28) -
Patient pain, 0-100 (mean) 32 (26-38) 33 (26-41) -
Patient global, 0-100 (mean) 32 (26-38) 31 (23-38) -
Level of morning stiffness, 0-100 (mean) 36 (29-43) 36 (27-44) -
Duration of morning stiffness, 0-100 (mean) 33 (26-41) 29 (20-38) -
Clinical scores
BASMI, 0-100 (median) 0 (0-0) 0 (0-10) -
Physician global, 0-100 (mean) 16 (13-20) 20 (16-25) -
Thoracic chest expansion in cm (mean) 4.1 (3.9-4.4) 4.9 (4.5-5.3) -
Test results
CRP in mg/L (median) 2.1 (1.3-3.9) 1.0 (0.5-2.5)
SIJ MRI activity, 0-40 (mean) 7.5 (5.9-9.0) 4.3 (2.9-5.7) -
Spine MRI activity, 0-81 (median) 1 (0-4) 1 (0-2) -
SIJ MRI chronicity, 0-48 (mean) 15 (12-18) 17 (13-22) -
Spine MRI chronicity, 0-207 (median) 0 (0-4) 0 (0-5) -

Numbers in parentheses are 95% confidence interval for measures with a Gaussian distribution and 25% to 75% percentiles for measures with a non-Gaussian distribution. aDisease duration was defined as duration since start of symptoms. -, not available; Anti-TNF-α, anti-tumor necrosis factor-alpha; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondilitis Metrology Index; CRP, C-reactive protein; HC, healthy control; MRI, magnetic resonance imaging; MTX, methotrexate; SIJ, sacroiliac joint; SpA, spondyloarthritis.

Kragstrup et al.

Kragstrup et al. Arthritis Research & Therapy 2014 16:R42   doi:10.1186/ar4471

Open Data